

## **VIA SIGNATURE CONFIRMED DELIVERY**

May 14, 2020

Mark J. Badria Pharmacist-in-Charge/Co-Owner Southern California Compounding Pharmacy, LLC 11125 Flintkote Avenue, Suite F San Diego, CA 92121-1213

Dear Mr. Badria:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Southern California Compounding Pharmacy, LLC, located at 11125 Flintkote Avenue, Suite F, San Diego, CA 92121-1213, from July 8, 2019, to August 1, 2019, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter sent to the California State Board of Pharmacy for follow up.

When the Agency considers an inspection to be "closed" under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please Maria Kelly-Doggett, Compliance Officer, at 425-302-0427, or by email at maria.kelly-doggett@fda.hhs.gov.

Sincerely,

CDR Steven E. Porter, Jr.

Director, Division of Pharmaceutical Quality Operations IV

Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine CA 92612-2506 Telephone: 949-608-2900

Fax: 949-608-4417 www.fda.gov